Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors Meeting Abstract
| Authors: | McKean, M.; Tolcher, A. W.; Reeves, J. A.; Chmielowski, B.; Shaheen, M. F.; Beck, J. T.; Orloff, M. M.; Somaiah, N.; Van Tine, B. A.; Drabick, J. J.; Spira, A. I.; O'byrne, K.; Karapetis, C. S.; Foresto, S. A.; Movva, S.; Martinez, J.; Li, M.; Winkler, R.; Yang, D.; Zhai, Y. |
| Abstract Title: | Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302336 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.9517 |
| Notes: | Meeting Abstract: 9517 -- Meeting also held virtually -- Source: Wos |
